Zobrazeno 1 - 10
of 889
pro vyhledávání: ''
Publikováno v:
Value Health
Objectives To estimate the effect of filgrastim-sndz market entry on patient out-of-pocket costs and claim payments for filgrastim products. Methods This study used a single interrupted time series design with longitudinal, nationally representative,
Autor:
Eric K. H. Chan, Elizabeth C. Hsia, John D. Reveille, Stephen Xu, L. Kim, Akgun Ince, Atul Deodhar, Kim Hung Lo, N Li, S. Peterson, Diane D. Harrison, Chenglong Han
Publikováno v:
Value in Health. 23:1281-1285
Evaluate the effect of intravenous golimumab on health-related quality of life (HRQoL) in patients with ankylosing spondylitis (AS) through week 28 of the phase III, multicenter, randomized, double-blind, placebo-controlled GO-ALIVE study.Adult patie
Autor:
G.M. Lanchoti Fiori, T. Teixeira Chadid, B. Mendes da Silva, I. Genov, C. Regis, B. Villas Boas
Publikováno v:
Value in Health. 24:S31-S32
Publikováno v:
Value in Health. 24:S14-S15
Autor:
Anders Himmelmann, P. Amarenco, Stefan James, H. Denison, J. Venditto, M. Knutsson, P. McEwan, O. Darlington, S. Evans, Carl Mellström, N. Atreja, S.C. Johnston, P. Ladenvall, A. Tank
Publikováno v:
Value in Health. 24:S70-S71
Publikováno v:
Value in Health. 20:1329-1335
Objectives To forecast lifetime outcomes and cost of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis (CF) with homozygous phe508del mutation from the US payer perspective. Methods A lifetime Markov model was developed from a
Publikováno v:
Value in Health. 23:S423-S424
Autor:
R. Belleli, H. Celik, A.Y. Castro, F. Lourenço, P. Orfanos, B. Pinheiro, Margarida Borges, M. Cardoso, L. Silva Miguel
Publikováno v:
Value in Health. 23:S437-S438
Publikováno v:
Value in Health. 23:S412-S413
Autor:
H. Kaur, I. Hasani, R. Olivenstein, M. Mtibaa, R. Ishikawa, J. Marvel, M. Muthukumar, Saransh Gupta
Publikováno v:
Value in Health. 23:S723-S724